VSTM
Verastem, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth +20.0% ·
share flow +30.0% ·
net new positions +16.7%
— formula
Broad accumulation — rising shares across more holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 65 | +6 | 39.97M | $152.90M | +11 | −5 |
| Q1 2026 | 61 | -1 | 34.42M | $182.56M | +5 | −6 |
| Q4 2025 | 62 | -1 | 31.11M | $240.18M | — | −1 |
| Q3 2025 | 17 | +2 | 20.72M | $182.92M | +3 | −1 |
| Q2 2025 | 12 | +1 | 11.06M | $45.90M | +1 | — |
| Q1 2025 | 8 | 0 | 4.53M | $27.31M | +1 | −1 |
| Q4 2024 | 8 | +1 | 3.00M | $15.49M | +2 | −1 |
| Q3 2024 | 6 | +1 | 1.09M | $3.27M | +3 | −2 |
| Q2 2024 | 5 | — | 667.62K | $1.99M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Geode Capital Management ✦ (passive) | 890.60K | +67.5% | $2.66M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 2 | Geode Capital Management ✦ (passive) | 890.60K | +67.5% | $2.66M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 3 | Two Sigma Investments ✦ | 100.55K | +897.0% | $300,630 | 0.0% | ▲ Add | 2 | SEC ↗ |
| 4 | Renaissance Technologies ✦ | 53.10K | New | $158,769 | 0.0% | New | 1 | SEC ↗ |
| 5 | AQR Capital Management ✦ | 31.31K | New | $93,617 | 0.0% | New | 1 | SEC ↗ |
| 6 | AQR Capital Management ✦ | 31.31K | New | $93,617 | 0.0% | New | 1 | SEC ↗ |
| 7 | AQR Capital Management ✦ | 31.31K | New | $93,617 | 0.0% | New | 1 | SEC ↗ |
| 8 | T. Rowe Price ✦ | 15.26K | New | $46,000 | 0.0% | New | 1 | SEC ↗ |
| 9 | Citadel Advisors ✦ | 2.93K | -90.4% | $8,758 | 0.0% | ▼ Trim | 2 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| Renaissance Technologies | $158,769 | 0.0% |
| AQR Capital Management | $93,617 | 0.0% |
| AQR Capital Management | $93,617 | 0.0% |
| AQR Capital Management | $93,617 | 0.0% |
| T. Rowe Price | $46,000 | 0.0% |
Exited
| Marshall Wace | $222,947 | was 0.0% |
| Millennium Management | $61,936 | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 154 holders, 81.36M shares, $428.32M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.